AQP2 and Ureteral obstruction: Pharmacological manipulation with angiotensin receptor blockers (e.g. candesartan) 99 or COX-2 inhibitors 100,101 might prevent the reduction in AQP2 down-regulation and post-obstructive polyuria, as seen in animal models of ureteral obstruction.